nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Arthur Holden: banking on our genes
|
Owens, Joanna |
|
2003 |
|
3 |
p. 78-81 4 p. |
artikel |
2 |
Chemogenomics identifies fusion tyrosine kinase
|
Habeck, Martina |
|
2003 |
|
3 |
p. 75-76 2 p. |
artikel |
3 |
Haemozoin (malaria pigment): a unique crystalline drug target
|
Egan, Timothy J. |
|
2003 |
|
3 |
p. 115-124 10 p. |
artikel |
4 |
It's a knockout!
|
Howard, JulieP. |
|
2003 |
|
3 |
p. 76-77 2 p. |
artikel |
5 |
One step closer to specific cancer drugs?
|
Sutherland, Stephani |
|
2003 |
|
3 |
p. 73-74 2 p. |
artikel |
6 |
Patent prosecution in proteomics
|
Chan, Keala |
|
2003 |
|
3 |
p. 81-84 4 p. |
artikel |
7 |
Potassium channel target for breast cancer
|
Foubister, Vida |
|
2003 |
|
3 |
p. 72-73 2 p. |
artikel |
8 |
Protein structure: discovering selective protein kinase inhibitors
|
Buchanan, Sean G. |
|
2003 |
|
3 |
p. 101-108 8 p. |
artikel |
9 |
Proteomic approaches for generating comprehensive protein interaction maps
|
Auerbach, Daniel |
|
2003 |
|
3 |
p. 85-92 8 p. |
artikel |
10 |
siRNA as a tool for streamlining functional genomic studies
|
Boese, Queta F. |
|
2003 |
|
3 |
p. 93-100 8 p. |
artikel |
11 |
Target validation requirements in the pharmaceutical industry
|
Winkler, Hans |
|
2003 |
|
3 |
p. 69-71 3 p. |
artikel |
12 |
The importance of alternative splicing in the drug discovery process
|
Levanon, Erez Y. |
|
2003 |
|
3 |
p. 109-114 6 p. |
artikel |